welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Medication Education: F.A.P. and Medicationhttps://www.youtube.com/watch?v=UOQ94Rse...
-
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsThe purpose of this registry is to colle...
-
Shrinking the SilenceI’m a 28 year old, living with two ver...
-
Familial Adenomatous Polyposis: Challenges and Pitfalls of Surgical TreatmentSurgical management of familial adenomat...
-
Gene Therapy for Familial Adenomatous PolyposisThe adenomatous polyposis coli (APC) ge...
-
2018 Rose Parade: colon, thyroid cancer survivor: embracing the ‘new me’Looking at her, you would never guess th...
-
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisBACKGROUND : Patients with familial aden...